Discover
BOLD
Boundless Bio, Inc.
2.48
2 x 1.78
2 x 3.16
bid
ask
-
0.02
0.80%
2 @ 05:54 AM
2.50 +0.02 (0.81%)
| Ytd | 106.67% | |
| 1y | 133.96% |
2.46
day range
2.52
0.96
52 week range
2.79
| Open | 2.47 | Prev Close | 2.50 | Low | 2.46 | High | 2.52 | Mkt Cap | 55.74M |
| Vol | 329.17K | Avg Vol | 1.35M | EPS | -2.49 | P/E | N/A | Forward P/E | -0.70 |
| Beta | N/A | Short Ratio | 2.01 | Inst. Own | 75.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.62 | 200-d Avg | 1.31 | 1yr Est | 14.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-02-06 | 2024-12 | -0.74 | N/A | N/A | N/A |
| 2024-11-07 | 2024-09 | -0.76 | -0.74 | 0.02 | 2.63% |
| 2024-08-12 | 2024-06 | -0.78 | N/A | N/A | N/A |
| 2024-08-12 | 2024-06 | -0.78 | -0.77 | 0.01 | 1.28% |
| 2020-02-26 | 2019-12 | -1.02 | N/A | N/A | N/A |
| 2019-11-07 | 2019-09 | -1.07 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-13 | Guggenheim | Downgrade | Buy | Neutral |
| 2024-04-22 | Leerink Partners | Upgrade | Outperform | |
| 2024-04-22 | Guggenheim | Upgrade | Buy | |
| 2024-04-22 | Piper Sandler | Upgrade | Overweight |
Profile
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-04-01 | ARCH VENTURE FUND IX, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-04-01 | BUROW KRISTINA M | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-04-01 | CRANDELL KEITH L. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-04-01 | LIM JONATHAN E | Director | 0.00 | Conversion of Exercise of derivative security |
| 2024-04-01 | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-04-01 | WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN I L | Beneficial Owner of more than 10% of a Class of Security | 556.23K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | FMR, LLC | 3.34M | 8.61M | 14.97% |
| 2024-09-29 | RA Capital Management, L.P. | 2.18M | 5.63M | 9.78% |
| 2024-09-29 | Nextech Invest Ag | 1.23M | 3.17M | 5.51% |
| 2024-09-29 | Redmile Group, LLC | 1.02M | 2.64M | 4.59% |
| 2024-09-29 | Wellington Management Group, LLP | 947.61K | 2.44M | 4.25% |
| 2024-09-29 | Citadel Advisors Llc | 718.53K | 1.85M | 3.22% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Growth Company Fund | 291.76K | 752.73K | 1.31% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 194.91K | 502.87K | 0.87% |
| 2024-10-30 | iShares Russell 2000 ETF | 185.64K | 478.95K | 0.83% |
| 2024-10-30 | Fidelity Growth Company K6 Fund | 92.21K | 237.90K | 0.41% |
| 2024-10-30 | Fidelity Series Growth Company Fund | 78.90K | 203.56K | 0.35% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 65.22K | 168.28K | 0.29% |